Literature DB >> 19452541

Novel chemotherapy approaches for cervical cancer.

Sujana Movva1, Lorna Rodriguez, Hugo Arias-Pulido, Claire Verschraegen.   

Abstract

Cancer of the cervix is the second most common malignancy among women worldwide. The last 20 years have lead to numerous advances in the medical management of locally advanced cervical cancer, including preventive vaccination, chemoradiation, and neoadjuvant chemotherapy. The treatment of metastatic disease is palliative at best. Platinum-based chemotherapy remains the standard of care for inoperable patients who have recurrent disease. However, because most patients initially receive concomitant platinum-based therapy with radiation, many recurrent tumors are refractory to platinum. The use of novel therapeutic approaches targeted to the carcinogenic processes that leads to the ontogenesis of cervical cancer should be promoted in clinical studies to improve patient outcomes.

Entities:  

Mesh:

Year:  2009        PMID: 19452541     DOI: 10.1002/cncr.24364

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review.

Authors:  Daniele Xavier Assad; Silvia Taveira Elias; Andréia Cristina Melo; Carlos Gil Ferreira; Graziela De Luca Canto; Eliete Neves Silva Guerra
Journal:  Oncol Lett       Date:  2016-09-20       Impact factor: 2.967

Review 2.  Therapeutic potential of marine peptides in cervical and ovarian cancers.

Authors:  Salman Ahmed; Haroon Khan; Sajad Fakhri; Michael Aschner; Wai San Cheang
Journal:  Mol Cell Biochem       Date:  2021-12-02       Impact factor: 3.396

3.  Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients.

Authors:  Rehana Qureshi; Himanshu Arora; Shilpi Biswas; Ahmad Perwez; Afreen Naseem; Saima Wajid; Gauri Gandhi; Moshahid Alam Rizvi
Journal:  Tumour Biol       Date:  2016-01-14

4.  Combined measurement of tumor perfusion and glucose metabolism for improved tumor characterization in advanced cervical carcinoma. A PET/CT pilot study using [15O]water and [18F]fluorodeoxyglucose.

Authors:  I Apostolova; F Hofheinz; R Buchert; I G Steffen; R Michel; C Rosner; V Prasad; C Köhler; T Derlin; W Brenner; S Marnitz
Journal:  Strahlenther Onkol       Date:  2014-02-18       Impact factor: 3.621

5.  Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation.

Authors:  Elad Milrot; Anna Jackman; Eliezer Flescher; Pinhas Gonen; Itzhak Kelson; Yona Keisari; Levana Sherman
Journal:  Invest New Drugs       Date:  2012-09-06       Impact factor: 3.850

6.  Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.

Authors:  Ming-Mo Hou; Xiaochun Liu; Jennifer Wheler; Aung Naing; David Hong; Robert L Coleman; Apostolia Tsimberidou; Filip Janku; Ralph Zinner; Karen Lu; Razelle Kurzrock; Siqing Fu
Journal:  Oncotarget       Date:  2014-11-30

Review 7.  PPI Modulators of E6 as Potential Targeted Therapeutics for Cervical Cancer: Progress and Challenges in Targeting E6.

Authors:  Lennox Chitsike; Penelope J Duerksen-Hughes
Journal:  Molecules       Date:  2021-05-18       Impact factor: 4.411

8.  Novel approaches for concurrent irradiation in locally advanced cervical cancer: platinum combinations, non-platinum-containing regimens, and molecular targeted agents.

Authors:  Giannis Mountzios; Aspasia Soultati; Dimitrios Pectasides; Meletios A Dimopoulos; Christos A Papadimitriou
Journal:  Obstet Gynecol Int       Date:  2013-05-21

9.  PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.

Authors:  Xiang-Rong Shu; Jing Wu; He Sun; Li-Qun Chi; Jin-Huan Wang
Journal:  Diagn Pathol       Date:  2015-09-28       Impact factor: 2.644

10.  A molecular understanding of D-homoestrone-induced G2/M cell cycle arrest in HeLa human cervical carcinoma cells.

Authors:  Renáta Minorics; Noémi Bózsity; Judit Molnár; János Wölfling; Erzsébet Mernyák; Gyula Schneider; Imre Ocsovszki; István Zupkó
Journal:  J Cell Mol Med       Date:  2015-07-31       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.